November: Episode 5 Watch time: 20 min
Are all IL-23s the same?
The fifth episode explores how differences within the IL-23 inhibitor class may affect efficacy, safety and dosing outcomes for patients with moderate to severe psoriasis, with a focus on IL-23p19 inhibitors, including SKYRIZI® (risankizumab).
Podcast Series Host
Podcast Guest Speakers
- SKYRIZI (risankizumab) Summary of Product Characteristics.
UK-RISN-210517 Date of Preparation: October 2021